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Introduction
Lung cancer is the most frequently diagnosed
oncologic disease worldwide. It is annually
diagnosed in nearly 1.4 million patients. It is
also the most frequent cause of cancer related
deaths [32]. In the Czech Republic, lung cancer
occupies a leading position both in the rate of
incidence and the mortality rate. In men, it is
the second most common oncologic disease
after prostate cancer, while in women it
assumes third position after breast and colon
cancer [31]. Lung (bronchogenic) carcinoma
are generally divided into two basic types:
a group of non-small-cell lung cancers
(NSCLC), which contributes to the total number
of lung cancers at the level of 75 to 80%, and
the small-cell lung cancer (SCLC) accounting
for the remaining 20 to 25%. Both types differ
from each other in regard to the biological
behaviour and prognosis, as well as the
treatment strategy [30], [31]. In 2010, the
incidence of this disease in men was 89.7 per
hundred thousand people (it was 102.3 in
1996), while in women it was 35.2 per hundred
thousand people (against 22.9 in 1996). The
severity of the disease is also reflected by the
high mortality rate which was 74.8 per hundred
thousand people in men in 2010 (87.9 in 1996)
and 27.4 per hundred thousand people in
women (19.5 in 1996) [28].
Cancer costs the EU are estimated as 126
billion EUR in 2009, with health care accounting
for 51 billion EUR. Lung cancer had the highest
economics cost 18.8 billion EUR. [11]. Up until
this point (second part of the year 2013), no
comprehensive study of healthcare costs for
lung cancer treatment in all stages of the illness
has been published in the Czech Republic. The
main object of this study is to make an assessment
of therapy related costs from the payers’
(health insurance funds) and the healthcare
providers’ (hospitals) perspective based on
some available and identifiable data from three
out of total thirteen Complex Oncology Centres
in the Czech Republic, namely Brno, Hradec
Králové and PlzeÀ, where the treatment
standards were set up [5], [20], [21], [30].
Several international studies have been
carried out in the European context using, as
a rule, so-called treatment algorithms for the
determination of therapeutic costs [1]. Based
on these algorithms, prices were successively
analysed applying mainly the analysis of
reimbursements based on DRG or on
published reimbursement lists [14], [25], [29].
All the studies mentioned here are based on
cost estimates. German study assessing the
social costs employed the principle based on
assessing the rate of human capital. The total
costs, including the absenteeism costs, were
thereby assessed. [27]. A retrospective study
carried out in the Netherlands assessed costs
from the initial diagnosis to subsequent death
or to the end of the assessment period. It
included the length of hospital stays, the types
and number of diagnostic procedures involved
and some information concerning radiotherapy
and chemotherapy [23]. A very widespread
approach is the assessment of treatment in
a particular stage [1]. The authors of a study on
this topic carried out in Switzerland came to the
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conclusion that a hospital stay is inexpedient in
terms of cost effectiveness [9]. In the UK and
the US, the so-called global studies analyse
also the social costs of lung cancer [4]. The
most extensive study of this type was published
in the USA, by means of the application of
diagnostic and therapeutic algorithms, the
results of which were supported by data from
a group of over 2,000 patients [15]. A study
written in Thailand, describes a sample group
of 96% of all patients with lung cancer
registered there in 2010. The treatment costs
were subdivided according to three schemes
currently employed in Thailand for healthcare
reimbursement [22].
According to Cipriano et al. [6], the monthly
treatment costs for a 72-year-old patient
diagnosed with lung cancer in 2000, ranged
from USD 2,687 (no active treatment) to USD
9,360 (chemo-radiotherapy) in the first 
6 months; costs varied by stage at diagnosis
and histologic type.
Vergnenègre et al [29] used a sample from
public and private hospitals treating large
numbers of patients. The study covered the
period from 1 July 1998 to 30 June 1999, and
was based on medical chart review. A Markov
model with six decision trees (two for small cell
lung cancer [SCLC] and four for non-small cell
lung cancer [NSCLC]) was used for the cost
analysis. The treatment was broken down into
first-line and second-line strategies, surveillance,
and terminal care (TC). The resulted average
management costs were EUR 22,006 (EUR
10,631–36,296) for 1 year and EUR 25,643
(EUR 10,631–41,191) for 2 years. The 2-year
average costs were EUR 22,420 for
disseminated SCLC and EUR 27,098 for
localized SCLC. The costs of NSCLC ranged
from EUR 19,543 for nonsurgical stages to
EUR 30,024 for surgical stages, and to EUR
24,383 for stage IV. The weight of the different
components of each strategy differed markedly
according to the diagnostic subgroup: the cost
of diagnosis ranged from 7.4% to 14% of the
total management costs, and that of TC ranged
from 11.5% to 31.1%. The principal cost
component was the first-line chemotherapy
(32–58.5%). Sensitivity analyses showed that,
whatever the type of lung cancer, the
percentage of actively treated patients was the
main cost determinant. TC and chemotherapeutic
lines also had important economic implications.
Dedes et al. [9] concluded that for the entire
patient sample in his study, the mean cost per
patient was EUR 19,408 (median EUR 14,691,
range EUR 1,821–80,020), 71% of which was
due to the hospitalisation costs. The mean cost
per a NSCLC patient was EUR 19,212 (median
EUR 14,511, range EUR 1,821–80,020), and
per a SCLC patient it was EUR 20,992 (median
EUR 15,367, range EUR 5,282–51,840).
Wolstenholme and Whynes [33] published
a detailed patient-by-patient cost analysis based
on case records for 253 patients diagnosed in
1993, revealing that the mean 4-year diagnosis
and treatment costs amounted to GBP 6,150
and GBP 5,668 for non-small cell and small cell
lung cancer resp. These costs are lower than
those identified in Canadian studies, the difference
being explained by the use of simulated costing
methodology, lower unit costs, and less
aggressive interventions.
Zeng et al [34] calculated the mean cost of
treatment for PFS and DPS patients; over one
year it was approximately USD 11,566 and
USD 14,519, respectively. The monthly costs
for all patients were higher initially than in the
subsequent months (PFS: USD 2,490; DPS:
USD 2,503). For PFS patients, healthcare
expenditures stabilised after the 7th month,
with the mean monthly medical expenditure of
USD 82.49. For DPS patients, expenditures
stabilised after the 9th month, and the mean
expenditure during the 9th month was USD 307.9.
Medical care costs in the three successive
months prior to death were USD 3,754, USD
5,829 and USD 7,372, respectively.
The majority of economic studies devoted
to lung cancer include only direct costs using
either simple cost-minimisation analyses, or complex
cost-benefit analyses [3], [17]. Specific eligible
costs vary between individual studies and
countries. The underlying reasons may be seen
in different data sources, a different organisation
of the health care system, its financing and
reimbursements [17]. The studies vary also e.g.
according to the respective patients’ populations,
the types of analyses, approaches or time
horizons, or by the afore mentioned type of
costs involved [4].
An OECD study published in 2013
summarised that cancer currently consumes
around 5% of all health care costs. Increasing
incidence, prolonged survival, and high costs of
novel drugs and technologies mean that growth
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in spending on cancer is outstripping growth in
total health expenditure. Cancer patients and
their carers also bear significant costs, both financial
and social. Once these are taken into account,
the global economic impact of premature death
and disability from cancer is around USD 900
billion, larger than that for heart disease, [19].
The conclusions of the OECD report are based
on estimates of health care related cost data.
This is considered a problem based in
unavailability of actual data, and the report
stresses the importance to move towards an
implementation of disease specific health
accounts in the future.
In Europe it is generally accepted that the
cost assessment should be left to the national
bodies, while the outcomes can be shared, as
they are usually results of a multi-centre
randomized controlled trial. E.g. the panel of V4
experts [10] concluded in December 2011 that
“... HTA decision making should be left to the
national level. This is due to varying standards,
costs, traditions and values.” Also the study
carried out by Schiller et al. [25] concluded that
differences in healthcare systems cause that
the results of cost/financial analyses may not
be generalizable to all countries/settings.
1. Methods and Sources of Data
Based on the analysis of the studies above,
a methodology was set up with the objective of
assessing costs for lung cancer treatment, both
from the payers’ and the healthcare providers’
perspectives. In the Czech Republic a similar
methodology was used in the study dealing
with costs of type II diabetes in 2009 [12]. We
also followed the methodological recommen-
dations formulated by the 2013 Report of the
ISPOR Health Economic Evaluation Publication
Guidelines Good Reporting Practices Task
Force. [13]
The costs spent in the Czech Republic by
the payer (health insurance funds) may be
calculated on the basis of publicly accessible
data, i.e. particularly the Decree No. 134/1998
Coll., which issues the list of medical proce-
dures with their point values [8]. This decree is
annually updated, and the calculations in this
study are based on some relevant data for
2013. The calculations using DRG codes are
based on information published on the website
of the National Reference Centre (NRC). It
primarily includes the codebook of relative
weights and the list of general tariffs of the
costs for services [18]. For the purposes of the
lung cancer therapy calculation, the calcula-
tions were made excluding complications and
comorbidities (hereinafter CC). The costs of
pharmaceuticals were included in all models.
Just in the case of hospital overhead
estimations, these costs were omitted due to
the danger of possible overestimation of the
hospital total overhead costs. In bronchogenic
carcinoma, complications and associated
diseases are highly individual and their costs
must be monitored separately so they were
excluded from the calculations. In the case of
chemotherapy, it must be said that all costs for
pharmaceuticals (including biological therapy)
are paid separately and, therefore, they are
included in individual calculations in this way.
It is, however, much more difficult to identify
the costs spent by the health care provider, as
the majority of hospitals and health care facilities
work with cost related data in the “confidential”
mode. For the purposes of this study, these
costs were estimated and verified based on
expert opinions of pulmonologists, oncologists,
head physicians and staff members of technical
and economic departments of two pneumo-
oncologic centres and three university hospitals
in the Czech Republic. Interviews with experts
were conducted in the period from November
2012 to February 2013 based on diagnostic
and therapeutic algorithms (whose selection is
described in the part Results) thanks to which
costs for individual interventions were specified.
To attain the total costs, overhead costs had to
be added. Based on consultations with experts,
overhead costs were additionally calculated to
include all costs, excluding drugs, i.e. mainly
chemotherapeutics and biological drugs. These
pharmaceuticals (primarily biological drugs)
form the dominant part of costs in numerous
therapeutic procedures. If overhead costs were
added to them, some results would arise and
be unlikely costs for therapy. In the final
consequence, the real situation would not be
reflected in this way.
The times of interventions are stated in
accordance with the data published in the lists
of procedures with point values for individual
medical branches [2], [8]. The salaries of
medical staff are calculated based on average
salaries and wages for 2011 published by the
Institute of Health Information and Statistics of
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the Czech Republic [16] (the latest data
released to date).
The calculated costs were noted directly
into the process maps; see an example in Figs.
1–3. The first figure presents all options of the
therapeutic scheme for the stage IIIB. Here,
individual calculations are not described for the
reason that they are specified in the following
therapeutic paths that follow from the basic
chart. Thus, the maps below (Fig. 2 and Fig. 3)
display two different paths that the clinician
may select during the treatment of broncho-
genic carcinoma in stage IIIB. In them, the
costs for the individual steps are already
demonstrated. If the schemes include a step
without the accompanying calculated costs, it is
not a therapeutic procedure. In this stage, it is
an intermediate step due to diagnostics. The
costs for these diagnostics are negligible if
compared with the costs for treatment as such.
All the data are expressed in Czech Crowns
(CZK). The CZK exchange rate ranged
between 25–26 CZK to EUR, or 19–20 CZK to
USD during the previous year [7]. All monetary
data were rounded to the nearest crown.
Fig. 1: Non-small-cell type of lung cancer – stage IIIB; basic chart
Source: Authors’ design based on recommended therapeutic procedures [5], [20], [21], [30]
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Source: Authors’ design based on recommended therapeutic procedures [5], [20], [21], [30]
Fig. 2: Non-small-cell type of lung cancer – first therapeutic path for stage IIIB
2. Results
The results presented in this study are
calculated based on some diagnostic and
therapeutic algorithms, i.e. process maps.
These, in turn, were designed, based on
recommended therapeutic procedures issued
by the Masaryk Institute of Oncology, the
University Hospital in Hradec Králové and the
University Hospital in PlzeÀ [5], [20], [21], [30].
Based on these issued therapeutic standards,
these maps were modified into their current
form. Procedures are subdivided according to
the above mentioned basic types of the disease
into small-cell lung cancer (SCLC) and non-
small-cell lung cancer (NSCLC). Each procedure
consists of diagnostics, therapy and the
subsequent monitoring of patients. The costs
for such respective steps were assessed in
individual blocks, and the total costs for the
particular therapeutic scheme were subsequently
calculated.
As an example, the therapeutic algorithm
for stage IIIB of NSCLC (Fig. 1–3) is
demonstrated. An entire set of process maps
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Fig. 3: Non-small-cell type of lung cancer – second therapeutic path for stage IIIB
Source: Authors’ design based on recommended therapeutic procedures [5], [20], [21], [30]
may be found in [26]. All calculations are
always based on the basic algorithm which is
successively subdivided into such individual
diagnostic or therapeutic paths. These paths
allowed us to calculate the costs for individual
therapeutic alternatives which a patient may
undergo. The term path is used in this context
to describe the therapeutic process undergone
by an individual patient based on a clinician’s
recommendations involving standard therapeutic
procedures. Hence, a path describes one of the
alternatives that a patient may undergo.
Algorithms in Figs. 1–3 are compiled according
to the above mentioned data capturing the
recommended diagnostic and therapeutic
procedures for stage IIIB of NSCLC. The
calculation of all the other recommended
alternatives (depending on the type and stage
of the disease) followed the same principle.
Using the procedure above, the costs for 32
utilized procedures (process maps) were
calculated. The costs for therapeutic processes
account for 22 results, while diagnostic
procedures account for 10 results. Both direct
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and indirect costs were included in some
individual calculations. The overview of costs
for all 32 processes is presented in Tabs. 1 and
2, whereby costs on the part of the health care
provider, health insurance payments (= the
payer’s costs), patient’s co-payments, and the
balance in the provider’s favour are included.
The patient’s co-payment (regulatory fee)
depends on the average time of treatment in
relation to which the numbers of regular
medical check-ups and the presumed length of
hospital stays are determined.
Tab. 1: Non-small-cell type of lung cancer: complete results (all data are in CZK)
Type of procedure Costs Payment from Co-payment Balance
instance
Dg. Path 1 32,926 33,726 0 800
Dg. Path 2 25,766 25,539 0 -226
Dg. Path 3 19,336 21,684 0 2,348
Dg. Path 4 26,496 29,871 0 3,375
Therapy IA Path 1 120,950 155,256 2,940 31,366
Therapy IA Path 2 77,673 108,602 5,290 25,639
Therapy IA Path 3 138,110 169,065 5,290 25,666
Therapy IB-IIIA Path 1 120,950 155,255 2,940 31,365
Therapy IB-IIIA Path 2 103,691 91,073 5,290 -17,907
Therapy IB-IIIA Path 3 132,493 169,065 5,290 31,282
Therapy IB-IIIA Path 4 132,493 169,066 5,290 31,283
Therapy IIIB Path 1 100,401 96,459 2,940 -6,882
Therapy IIIB Path 2 71,770 120,147 2,940 45,437
Therapy IV Path 1 69,487 94,792 2,700 22,605
Therapy IV Path 2 519,810 579,040 2,700 56,530
Therapy IV Path 3 582,050 608,075 2,700 23,325
Monitoring for T1 N0 82,723 86,028 0 3,305
Monitoring – inoperable dinase 69,704 78,256 0 8,523
Monitoring of metastases 55,354 63,872 0 8,518
Source: Authors’ calculation based on the procedure described in the sections Methodology and Results.
Remark: TNM – international classification of the disease extent
T1 N0 – disease in the least possible stage
The DRG system sets “average” reimburse-
ments for all procedures (diagnostic and
therapeutic) connected with the given diagnosis
(weighted average depending on the number of
patients in individual alternatives). By its very
nature, therefore, the health insurance company
does not consider different alternative therapies,
but acknowledges on behalf of the hospital
a “standardised” reimbursement for any type of
treatment for the given diagnosis. The system
according to the authors was that deviations
from the average would be mutually compensated,
and this system would simplify all reporting. It is
not the purpose of this article to describe the
actual handling of the DRG system in the whole
system within the Czech health care system,
nor in individual hospitals. In general we do not
mind that the reimbursement of the care is
underestimated. In terms of the diagnostics and
treatment of bronchogenic carcinoma, only 6
diagnostic groups come into account presented
in Tab. 3 (CC standing for complications and
commorbidities).
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Tab. 2: Small-cell type of lung cancer: complete results (all data are in CZK)
Type of procedure Costs Payment from Co-payment Balance
insurance
Dg. Path 1 16,324 16,681 0 357
Dg. Path 2 22,754 20,778 0 -19,758
Dg. Path 3 33,754 32,147 0 -1,606
Dg. Path 4 27,324 26,091 0 -1,233
Therapy for an extensive disease Path 1 102,685 107,985 2,255 3,046
Therapy for an extensive disease Path 2 73,008 51,120 2,255 -24,143
Therapy for an extensive disease Path 3 80,658 109,555 2,255 26,642
Therapy for a limited disease Path 1 130,096 177,954 2,549 45,309
Therapy for a limited disease Path 2 138,657 239,738 2,549 98,532
Therapy for a limited disease Path 3 90,246 104,635 2,549 11,840
Therapy for a limited disease Path 4 122,308 183,580 2,549 58,722
Monitoring of a limited disease 21,375 23,200 0 1,825
Monitoring of an extensive disease 2,553 2,733 0 180
Source: Authors’ calculation based on the procedure described in the sections Methodology and Results.
DRG reimbursement = cost weight × (basic rate + additional factors) (1)
Tab. 3: Reimbursements using the DRG system
Group Reimbursement amount
Radiotherapy without CC 1.2552 × (37,279+1,497) = CZK 48,672
Chemotherapy without CC 0.6824 × (20,269+10,917) = CZK 21,281
Major chest surgery without CC 3.1129 × (92,453+12,812) = CZK 327,679
Minor chest surgery without CC 2.5833 × (76,725+15,220) = CZK 237,522
Malign diseases of respiratory system without CC 0.6493 × (19,285+1,752) = CZK 13,659
Syndromes, symptoms and other diagnoses of the 
respiratory system without CC
0.4140 × (12,296+222) = CZK 5,182
Source: NRC and authors’ calculation
3. Discussion
The study presents some cost calculations for
individual diagnostic and therapeutic
procedures at different stages of bronchogenic
carcinoma. The calculations of disease related
costs are always based on one standard
treatment algorithm that is recommended and
typical of the particular patient’s performance
status. Genuine patients with lung cancer,
however, continuously fight the disease and,
therefore, they participate in several of these
therapeutic schemes. The treatment in practice
may differ from recommended standards as the
clinician must react to the patient’s current
status at any given moment. Moreover, there
are other symptoms that usually also interfere
in the course of such severe diseases, and it is
very difficult to distinguish whether they have
been caused by the tumour or are independent
of it. This, however, does not affect the
calculation of the cost rates for the individual
stages in the therapeutic process.
In the case of SCLC and NSCLC diagnostic
procedures, the assumption that the health
Reimbursements are calculated applying the following formula:
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care provider covers their costs may be
confirmed with a high level of reliability.
Diagnostic methods may be divided into
imaging, laboratory and surgical methods. The
reimbursements for imaging and surgical
diagnostics cover actual costs of the health
care providers. With respect to laboratory
methods, this is not necessarily the case.
Based on our own calculations, we estimate
that the reimbursement represents a mere 61%
of the incurred costs. The costs for laboratory
methods are not essential for the health care
providers as they account for a relatively small
portion of the total costs that mainly include the
costs for therapies.
A more detailed analysis of costs relating to
non-small-cell lung cancer revealed that the
health care provider’s financial balance is
predominantly positive. These are usually
amounts with a maximum positive balance of
CZK 56,530. However, the total costs on the
part of hospitals, as well as payers are higher.
The increase in costs is mainly caused by the
prescribing of biological drugs. If this therapeutic
procedure is not applied, the costs on the part
of the health care provider, reach the maximum
amount of CZK 143,399.60. It must also be
mentioned that the time of treatment was
calculated based on published studies where
the average survival time was 7.8 months. In
reality, however, the health insurance company
reimburses targeted drugs only after the
progression of the disease may be manifested
e.g. not earlier than after 20 months, which
further significantly increases the actual costs.
This also increases the reimbursements on the
part of the health insurance company and,
therefore, also the positive balance on the part
of the health care provider.
With respect to the calculation of the small-
cell lung cancer therapy, the provider again
reaches a positive balance. The most
significant financial benefit for the provider is in
the case of a so-called limited disease (one of
the forms of SCLC where radiotherapy plays an
indispensable role). Radiotherapy significantly
affects the resulting costs. In the calculation of
the X-ray scheme for SCLC, for example, the
health insurance company reimburses CZK
75,595, while the actual estimated costs
amount to CZK 18,107. This difference allows
the health care provider to compensate for the
methods that may result in a negative balance
owing to reimbursements. The situation is
solved by the DRG system that corresponds
more to the actual costs. The amounts of DRG
reimbursements are presented in Tab. 3.
The patient’s co-payments represent above
all, the so-called regulatory fees. These are
incomes for health care facilities. If they exceed
the limit set for a year (CZK 5,000, or CZK
2,500 for certain groups of patients in 2013),
they are reimbursed to patients. This, however,
does not affect the balance of the health care
facilities.
Conclusions
The calculations above imply that treatment
costs significantly differ depending on the
selected diagnostic and therapeutic procedures.
It also becomes apparent that the setting of the
reimbursement system presently generates
different stimuli for providers who may reach
both positive and negative balances. This fact,
in turn, may have an effect on the economic
result leading as a consequence thereof, to the
preference of alternatives more suitable in
terms of reimbursement regardless of the
optimum procedures for the particular patient.
This fact is, to some extent, reflected by
reimbursements calculated by means of the
DRG system. The existing legal regulations
and relations between individual actors create
a situation, whereby it is complicated to obtain
full information for the calculation of costs.
Therefore, the costs on the part of the provider
presented here are expert estimates based
partly on publicly available sources and partly
on expert opinions, which is a limiting factor
with respect to the above calculations. We are
of the opinion that the resulting costs modelled
and presented in this study may truly reflect the
situation in Czech hospitals (see also [24]). In
the same way, we may assume that there are
differences among health care providers both
with respect to the specific costs and to those
declared to assess such working costs that will
give rise to accurate calculations for a particular
hospital and a respective type of care in
general.
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Abstract
THE COSTS AND REIMBURSEMENTS FOR LUNG CANCER TREATMENT
AMONG SELECTED HEALTH CARE PROVIDERS IN THE CZECH REPUBLIC
Jana ·imrová, Miroslav Barták, Radovan Vojtí‰ek, Vladimír Rogalewicz
The objective of the article is to objectivise and assess the costs for the lung cancer therapy from
the payer’s (health insurance company) and the healthcare provider’s (hospital) perspective based
on information available from several large hospitals and specialised centres. No comprehensive
assessment of costs related to the treatment of lung cancers at all stages has been published in
the Czech Republic to-date. The results in this study are calculated based on diagnostic and
therapeutic algorithms, i.e. process maps. These, in turn, are derived from the recommended
therapeutic procedures issued by the Masaryk Institute of Oncology, the University Hospital in
Hradec Králové and the University Hospital in PlzeÀ. In total, the costs and reimbursements were
calculated for 32 utilized algorithms, i.e. process maps. The costs for therapeutic processes
account for 22 results, while 10 results correspond to diagnostic processes. Both direct and indirect
costs were included in individual calculations. The calculations imply that treatment costs
significantly differ depending on the selected diagnostic and therapeutic procedure. It becomes
apparent that the setting of the reimbursement system presently generates different stimuli for
providers, who may reach both positive and negative balances. This fact, in turn, may have an
effect on the economic result leading, in its consequence, to the preference of more suitable
alternatives in terms of reimbursement regardless of the optimum procedures for the particular
patient. This fact is, to a certain extent, reflected by the reimbursements calculated by means of
the DRG system. The given algorithms may potentially be used by health care providers to reach
working costs, which will allow accurate calculations for particular hospitals.
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JEL Classification: I12.
DOI: 10.15240/tul/001/2014-3-007
EM_03_14_zlom  28.8.2014  9:45  Stránka 85
